Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • FDA approves Novartis...

    FDA approves Novartis biosimilar to Amgens Enbrel

    Written by savita thakur thakur Published On 2016-09-01T13:17:09+05:30  |  Updated On 1 Sept 2016 1:17 PM IST
    FDA approves Novartis biosimilar to Amgens Enbrel

    The U.S. Food and Drug Administration approved Novartis AG's biosimilar version of Amgen Inc's arthritis drug Enbrel.


    The FDA approved the drug, Erelzi, known also as etanercept-szzs, for multiple inflammatory conditions including rheumatoid arthritis and plaque psoriasis, a skin condition.


    The agency approved the drug as a biosimilar, meaning there are no clinically meaningful differences between Erelzi and Enbrel. But the two drugs are not considered interchangeable and are therefore not called generics.


    Enbrel is a biologic drug made from living cells. Biologics are more difficult to imitate.


    The FDA's ruling followed a unanimous vote by the agency's advisory panel in July in favor of approval.


    "We are committed to bringing Erelzi to the U.S. market as soon as possible," said Carol Lynch, global head of biopharmaceuticals at Novartis' Sandoz unit in Germany.


    Enbrel was approved in 1998 and generated more than $5 billion in U.S. sales last year. It works by blocking a protein known as tumor necrosis factor, or TNF, that plays a role in inflammatory conditions.


    Amgen believes Enbrel has U.S. patent protection until 2029 and is fighting in court to keep Novartis' drug off the market.


    The FDA is also weighing approval of Amgen's biosimilar version of AbbVie's arthritis drug Humira, a TNF inhibitor that last year generated U.S. sales of more than $8 billion.


    AbbVie is in turn trying to block Amgen's drug from reaching the market, saying it has patents in place to protect Humira in the United States until at least 2022.

    AbbVieAmgenarthritis drugCarol LynchEnbrelErelzietanercept-szzsFDA approvedHumiraNovartisrheumatoid arthritisUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok